These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 772517)

  • 1. Clinical trials with bis-dioxopiperazine propane (ICRF 159; NSC 129, 943) in acute leukaemias.
    Krepler P; Pawlowsky J
    Osterr Z Onkol; 1975; 2(4):112-4. PubMed ID: 772517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Limited activity of ICRF-159 in advanced acute leukemia.
    Bakowski MT; Prentice HG; Lister TA; Malpas JS; McElwain TJ; Powles RL
    Cancer Treat Rep; 1979 Jan; 63(1):127-9. PubMed ID: 369684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ICRF-187 in clinical oncology.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    Cancer Clin Trials; 1981; 4(2):143-6. PubMed ID: 6788388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of the lymphomata with ICRF 159 (NSC 129943) adjunctive to combination chemotherapy.
    Garrett MJ; Das S
    Ir Med J; 1977 Oct; 70(15):460-1. PubMed ID: 924753
    [No Abstract]   [Full Text] [Related]  

  • 5. ICRF 159, (+/-) 1,2-di(3,5-dioxopiperazin-1-yl) propane NSC-129,943; razoxane.
    Bakowski MT
    Cancer Treat Rev; 1976 Jun; 3(2):95-107. PubMed ID: 821609
    [No Abstract]   [Full Text] [Related]  

  • 6. Effects of the L isomer (+)-1,2-bis(3,5-dioxopiperazine-1-yl)propane on cell survival and cell cycle progression of cultured mammalian cells.
    Traganos F; Darzynkiewicz Z; Melamed MR
    Cancer Res; 1981 Nov; 41(11 Pt 1):4566-76. PubMed ID: 6171341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of advanced adenocarcinoma of the kidney with ICRF-187: a Southeastern Cancer Study Group Trial.
    Brubaker LH; Vogel CL; Einhorn LH; Birch R
    Cancer Treat Rep; 1986 Jul; 70(7):915-6. PubMed ID: 3087618
    [No Abstract]   [Full Text] [Related]  

  • 8. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 9. Cell cycle progression and chromosome segregation in mammalian cells cultured in the presence of the topoisomerase II inhibitors ICRF-187 [(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane; ADR-529] and ICRF-159 (Razoxane).
    Gorbsky GJ
    Cancer Res; 1994 Feb; 54(4):1042-8. PubMed ID: 8313360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [New drugs for the therapy of acute leukemia].
    Massimo L; Comelli A
    Minerva Med; 1975 Jul; 66(52):2568-76. PubMed ID: 50581
    [No Abstract]   [Full Text] [Related]  

  • 11. Combination chemotherapy for advanced colorectal cancer with triazinate, ICRF-159, 5-FU, and methyl-CCNU.
    Vogl SE; Qazi R; Berenzweig M
    Cancer Treat Rep; 1980; 64(10-11):1143-5. PubMed ID: 7459902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of topoisomerase II by antitumor agents bis(2,6-dioxopiperazine) derivatives.
    Tanabe K; Ikegami Y; Ishida R; Andoh T
    Cancer Res; 1991 Sep; 51(18):4903-8. PubMed ID: 1654204
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ADR-529 (ICRF-187).
    Cancer Invest; 1989; 7(1):101. PubMed ID: 2500223
    [No Abstract]   [Full Text] [Related]  

  • 14. Phase II study of dianhydrogalactitol and ICRF-159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy.
    Ahmann DL; O'Connell MJ; Bisel HF; Edmonson JH; Hahn RG; Frytak S
    Cancer Treat Rep; 1977; 61(1):81-2. PubMed ID: 324622
    [No Abstract]   [Full Text] [Related]  

  • 15. Phase II trial of razoxane (ICRF-159) in patients with squamous cell carcinoma of the head and neck previously exposed to systemic chemotherapy.
    Shah MK; Engstrom PF; Catalano RB; Paul AR; Bellet RE; Creech RH
    Cancer Treat Rep; 1982 Mar; 66(3):557-8. PubMed ID: 7060043
    [No Abstract]   [Full Text] [Related]  

  • 16. Enhancement of the effectiveness of daunorubicin (NSC-82151) or adriamycin (NSC-123127) against early mouse L1210 leukemia with ICRF-159 (NSC-129943).
    Woodman RJ; Cysyk RL; Kline I; Gang M; Venditti JM
    Cancer Chemother Rep; 1975; 59(4):689-95. PubMed ID: 1175163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of ICRF-159 in non-Hodgkin's lymphomas.
    Flannery EP; Corder MP; Sheehan WW; Pajak TF; Bateman JR
    Cancer Treat Rep; 1978 Mar; 62(3):465-7. PubMed ID: 348318
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment of Kaposi's sarcoma with ICRF-159 (NSC-129943).
    Olweny CL; Masaba JP; Sikyewunda W; Toya T
    Cancer Treat Rep; 1976 Jan; 60(1):111-3. PubMed ID: 1000514
    [No Abstract]   [Full Text] [Related]  

  • 19. Study of cytosine arabinoside (NSC-63878) synchronization plus vincristine (NSC-67574), prednisone (NSC-10023), and L-asparaginase (NSC-109229) for remission induction in advanced acute leukemia in children.
    Sutow WW; Thomas D; Steuber CP; Pullen J; Vats T; Bryan JH; Morgan SK
    Cancer Treat Rep; 1976 May; 60(5):591-4. PubMed ID: 991148
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Eastern Cooperative Oncology Group phase II studies in advanced measurable colorectal cancer. I. Razoxane, Yoshi-864, piperazinedione, and lomustine.
    Douglass HO; MacIntyre JM; Kaufman J; Von Hoff D; Engstrom PF; Klaassen D
    Cancer Treat Rep; 1985 May; 69(5):543-5. PubMed ID: 2988774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.